Samay is a developer of an innovative AI-enabled wearable device focused on remote respiratory health management. The company addresses the growing need for effective chronic obstructive pulmonary disease (COPD) diagnostics and management, projected to incur significant healthcare costs in the coming years. Their patented chest patches provide passive monitoring of lung function, achieving 90% accuracy in COPD diagnosis and 83% accuracy in detecting exacerbation biomarkers. The device continuously tracks vital respiratory metrics, including pulmonary volumes, heart rates, and breathing sounds for two weeks, offering users valuable insights to optimize their respiratory health. Additionally, Samay is creating an AI-assisted management platform that supports patients and healthcare providers throughout the care continuum, enhancing personalized care from the comfort of home.
APrevent Medical
Non Equity Assistance in 2024
APrevent Medical Inc. is a medical device company founded in 2014 and headquartered in Taipei, Taiwan, with an additional office in Austria. The company specializes in developing therapeutic medical devices aimed at enhancing the quality of life for patients suffering from speech disorders. APrevent Medical focuses on innovative solutions, including a long-term implant system and a speech conversion platform, designed to provide minimally invasive treatments and support for voice and communication issues. By integrating advanced technologies, the company aims to offer effective interventions that enable patients to improve their speech capabilities and overall communication.
SmartCardia
Non Equity Assistance in 2024
SmartCardia SA is a Swiss company, established in 2013 and based in Lausanne, that specializes in the design and development of cardiac monitoring devices and cloud-based AI software. The company focuses on real-time patient monitoring by integrating advanced medical wearable technology with artificial intelligence. SmartCardia has created SmartNeuralNet, a cutting-edge machine learning technology that enhances their medical wearables. These ultra-small devices are designed to continuously track vital bio-signals, including heart rate, breathing rate, and skin conductance, allowing patients to monitor their health effectively. Through a dedicated mobile application, SmartCardia aims to provide actionable insights to individuals with chronic conditions, ultimately empowering them to improve their overall health management.
Nurami
Non Equity Assistance in 2024
Nurami Medical Ltd., established in 2014 and based in Haifa, Israel, is a clinical-stage medical device company specializing in the development of innovative solutions for soft tissue repair and regeneration following surgeries. The company's flagship product is a dural substitute patch, designed to replace damaged dura mater during neurosurgeries, promoting enhanced healing and patient recovery. Nurami's technology, based on electrospinning, creates a porous scaffold matrix that facilitates tissue regeneration and incorporates a temperature-sensitive sealant to prevent infections and cerebrospinal fluid leaks. The company aims to address unmet surgical needs and improve patient outcomes across various surgical procedures.
Arsenal Medical
Non Equity Assistance in 2024
Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, focused on developing innovative polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company specializes in creating in-situ forming foams designed to deliver local therapy for acute hemorrhage and other critical conditions such as vascular injury and repair. Arsenal Medical has developed two proprietary technology platforms: its therapeutic foam and AxioCore, a novel nanofiber technology that facilitates cell integration and tissue regeneration by enabling controlled delivery of biologics and therapeutics. The company utilizes safe, non-toxic, and biocompatible materials to enhance therapy in complex medical scenarios, positioning itself at the forefront of advancements in local treatment approaches.
SanaHeal
Non Equity Assistance in 2024
SanaHeal develops bioadhesive medical technologies designed for rapid and strong adhesion to wet and irregular tissue surfaces. Their platform features nature-inspired adhesives modeled after barnacles and spider webs, providing instant drying and secure attachment in moist environments.
Solenic Medical
Non Equity Assistance in 2024
Founded in 2019, Solenic Medical specializes in the development of a non-invasive medical device that uses alternating magnetic fields to eradicate biofilm on metallic implants. Its technology aims to address complications arising from surgeries like knee and hip replacements, as well as trauma-related implants.
Samay
Non Equity Assistance in 2024
Samay is a developer of an innovative AI-enabled wearable device focused on remote respiratory health management. The company addresses the growing need for effective chronic obstructive pulmonary disease (COPD) diagnostics and management, projected to incur significant healthcare costs in the coming years. Their patented chest patches provide passive monitoring of lung function, achieving 90% accuracy in COPD diagnosis and 83% accuracy in detecting exacerbation biomarkers. The device continuously tracks vital respiratory metrics, including pulmonary volumes, heart rates, and breathing sounds for two weeks, offering users valuable insights to optimize their respiratory health. Additionally, Samay is creating an AI-assisted management platform that supports patients and healthcare providers throughout the care continuum, enhancing personalized care from the comfort of home.
Progressive Nuero
Non Equity Assistance in 2024
Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.
X-BOLT Orthapaedics
Non Equity Assistance in 2024
X-BOLT Orthopaedics developed a novel expanding bolt device, with associated implants and instrumentation systems, for internal bone fixation in osteoporotic hip fractures. X-BOLT hip plating and nailing systems allow surgeons choice to treat all morphologies of proximal femoral fractures.
HealthTech Connex
Non Equity Assistance in 2024
HealthTech Connex is a brain technology company based in the Health and Technology District. It specializes in translational neuroscience innovations aimed at improving neurological performance and overall health outcomes. The company's technology evaluates an individual's cognitive brain health across various conditions, including brain injuries, neurological diseases, and optimization. This enables mental health professionals to detect cognitive impairments related to mental health issues early. By bridging the gap between laboratory capabilities and real-world applications, HealthTech Connex provides valuable services to care and community sectors globally.
Promedius
Non Equity Assistance in 2024
Founded in 2019, Promedius is a company dedicated to transforming the approach to aging through innovative technologies aimed at the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. Promedius has developed PROS® CXR:OSTEO, a pioneering screening solution that utilizes chest X-ray images combined with artificial intelligence to identify individuals at risk for osteoporosis. This technology is designed to prevent severe fractures among the elderly population, facilitating timely intervention and enhancing the overall quality of life. By harnessing AI in medical imaging, Promedius aims to support healthcare professionals in their efforts to improve patient outcomes and extend healthy lifespans.
CytoVeris
Non Equity Assistance in 2024
CytoVeris develops optical-based technologies that assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgery. Its devices enhance surgeons' ability to achieve clean margins, while its OncoMap system detects molecular signatures unique to cancer cells. Founded by Alan Kersey in Farmington, Connecticut in 2018.
REMEDI
Non Equity Assistance in 2024
REMEDI is a solution provider for radiotherapy and radiography.
Nanochon
Non Equity Assistance in 2024
Nanochon is developing an implantable, 3D-printed cartilage implant designed to replace damaged cartilage and promote new tissue growth in joints, with a focus on knee damage. The device combines 3D printing and a novel nanomaterial to enable on-demand, cost-effective solutions intended to restore joint function and improve outcomes for young and active patients.
Astek Diagnostics
Non Equity Assistance in 2024
Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.
Flow Medical
Non Equity Assistance in 2024
Flow Medical specializes in the development of multi-function catheters aimed at diagnosing and treating venous thromboembolic illnesses, including pulmonary embolism. The company's innovative platform enhances clot visualization and allows for the targeted delivery of clot-dissolving medication directly to the site of blockage. Additionally, it provides real-time monitoring of treatment progress, enabling clinicians to tailor therapy to the specific needs of each patient. Through its advanced catheter technology, Flow Medical seeks to improve patient outcomes in the management of thrombotic conditions.
NeuSpera Medical
Non Equity Assistance in 2024
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
Lattice Medical
Non Equity Assistance in 2024
Lattice Medical is a French medical device company focused on breast reconstruction after cancer. It designs and manufactures implantable devices that promote regeneration of autologous adipose tissue to enable natural breast reconstruction following mastectomy. The flagship implant, MATTISSE, uses 3D printing and fully biodegradable materials to provide personalized reconstruction in a single surgery, reducing operative time and invasiveness. The company aims to offer an alternative to silicone-based implants by supporting tissue regeneration rather than replacement. Founded in 2017 and based in Loos, France, Lattice Medical develops solutions to address clinical and societal needs by restoring form and function for women recovering from breast cancer.
EndoVision
Non Equity Assistance in 2024
EndoVision Limited, established in 2018 and headquartered in Hong Kong, specializes in the development of advanced artificial intelligence software aimed at enhancing computer-aided diagnosis in endoscopy. The company's innovative technology integrates AI to improve diagnostic accuracy and efficiency, positioning it as a significant player in the medical technology sector. Through its focus on leveraging artificial intelligence, EndoVision seeks to transform endoscopic procedures and contribute to better patient outcomes in the healthcare industry.
Invicta Medical
Non Equity Assistance in 2024
Invicta Medical develops innovative medical technologies for advanced sleep apnea treatments. Founded in 2013, the company is headquartered in Santa Clara, California.
VinBrain
Non Equity Assistance in 2024
VinBrain is a healthcare technology company that specializes in artificial intelligence applications within the medical field, particularly in medical imaging and diagnostics. The company offers DrAidTM Teleradiology, a remote medical imaging solution that facilitates the connection of resources and expertise between hospitals, ensuring patients receive quality diagnostic imaging services anytime and anywhere. VinBrain's platform enhances patient outcomes by identifying and distinguishing various types of cancerous cells and tissues, analyzing medical histories to pinpoint potential risk factors, and automatically generating reports based on healthcare data. Utilizing computer vision and generative AI, the company streamlines radiologists' workflows, providing healthcare providers with valuable insights to improve diagnosis, treatment, and overall patient care, while also enhancing operational efficiency.
ATDev
Non Equity Assistance in 2024
ATDev specializes in assistive technology and medical devices, focusing on mobility solutions. It develops robotic devices designed to enhance physical therapy accessibility and outcomes, enabling remote patient monitoring through telehealth services.
BrainSpace
Non Equity Assistance in 2024
BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.
NanoBioFAB
Non Equity Assistance in 2024
NanoBioFAB is a company based in Frederick, Maryland, specializing in the development of wearable, smart healthcare and medical devices utilizing nanotechnology. Founded in 2015, the company produces innovative products such as iNose, a device that allows individuals to detect, track, and monitor their body’s skin vapor-print. This device connects wirelessly to mobile phones, enabling users to track their fat burning rate, assess the effectiveness of their exercise routines, and observe the long-term effects of their dietary choices on metabolic rates. Additionally, NanoBioFAB offers nanoprinting technology and artificial intelligence sensors aimed at enhancing telemedicine and personalized healthcare solutions. The company is dedicated to making advanced healthcare accessible and affordable for both people and pets.
Robeaute
Non Equity Assistance in 2024
Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.
Nanotis
Non Equity Assistance in 2024
Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices aimed at addressing challenges in infectious disease testing, particularly for influenza. The company manufactures microchip-based devices that allow users to quickly and accurately diagnose illnesses. By providing early diagnosis solutions, Nanotis supports medical professionals in practical healthcare settings, thereby enhancing the efficiency of healthcare delivery and improving patient outcomes.
Aurie
Non Equity Assistance in 2024
Aurie is a medical device company founded in 2018 and headquartered in New York, United States. The company specializes in developing a reusable urinary catheterization system aimed at empowering individuals with disabilities. Aurie's innovative system is designed to provide convenient, discreet, and hygienic options for catheterization, significantly reducing the risk of infection. By enhancing user confidence and control, Aurie's product enables individuals to manage their condition more effectively, fostering greater independence and the ability to lead active, fulfilling lives.
Craif
Non Equity Assistance in 2024
Craif develops innovative devices for early cancer detection using urine tests. Founded in 2018, the company aims to improve cancer survival rates by enabling painless, accurate, and regular diagnosis through its MicroRNA technology.
TYBR Health
Non Equity Assistance in 2024
TYBR Health is a medical device company that develops a sprayable hydrogel to reduce internal scarring after surgery. The hydrogel, derived from natural sources, has shown a 75% reduction in scarring in preclinical studies. It is applied through a steerable device that can be used in both open and minimally invasive procedures, helping surgeons protect healing tissues and improve recovery outcomes. Founded in 2020 by Tim Keane and Alex Smith in Houston, Texas, the company focuses on simplifying postoperative care and enhancing the healing response of internal organs.
INIA Biosciences
Non Equity Assistance in 2024
INIA Biosciences is a developer of innovative medical devices that leverage sound wave technology to create non-invasive, home-administered systems for managing chronic inflammatory diseases. The company focuses on a closed-loop monitoring system designed to treat and prevent organ failure by integrating biomarker monitoring with an ultrasound stimulator. This approach aims to reduce inflammation linked to transplant rejection rates and minimize reliance on immunosuppressant drugs. By providing novel diagnostic sensing capabilities, INIA Biosciences enables physicians to better manage chronic diseases and improve patient outcomes.
Butterfly Medical
Non Equity Assistance in 2024
Butterfly Medical Ltd is a medical-device company founded in 2014 and based in Yokne'am, Israel. It specializes in the development of an implantable device aimed at treating Benign Prostatic Hyperplasia (BPH), a condition commonly referred to as enlarged prostate. The company's innovative device provides a fast, simple, and minimally invasive alternative to conventional BPH treatments, including medications and surgery. It can be implanted in under ten minutes in an office setting using local anesthesia, without the need for surgical incisions or removal of prostate tissue. This approach not only minimizes side effects but also eliminates the requirement for hospitalization or general anesthesia. Initial clinical trials have shown promising results, with effective outcomes in opening blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies in leading medical centers across Europe to validate its device's efficacy and safety.
Fasciotens
Non Equity Assistance in 2024
Fasciotens is a medical technology company based in Essen, Germany, focused on open abdomen therapy. The company develops a medical device designed to treat patients requiring an open abdomen by keeping the abdominal wall under tension and regulating intraabdominal volume, combining mesh-mediated traction with an external fixator concept to improve survival in critically ill patients. The device aims to prevent retraction of the abdominal wall and enable delayed closure, addressing situations such as abdominal compartment syndrome, severe infections, postoperative complications, or trauma.
Biometry
Non Equity Assistance in 2024
myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.
Salvia BioElectronics
Non Equity Assistance in 2024
Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.
Surgical Automations
Non Equity Assistance in 2024
Surgical Automations specializes in the development of surgical robots and automation technologies aimed at improving patient safety and reducing medical errors. The company offers an AI-based autonomous robotic navigation system tailored for endoscopic diagnostic and interventional procedures. Their innovative approach includes an automated endotracheal intubation system that accurately detects the trachea's opening and facilitates the insertion of the endotracheal tube. This technology significantly enhances the precision of surgical procedures, enabling medical professionals to minimize risks and improve outcomes during operations.
Ortho-tag
Non Equity Assistance in 2024
Ortho-tag is a developer of innovative in-vivo platforms that facilitate the connection between digital health applications and implanted biosensors within the human body. The company's technologies focus on enhancing wireless communication with medical devices through proprietary transcutaneous volume conduction. This enables real-time data exchange, in-vivo storage, and the integration of nanodiagnostic and therapeutic functions in smart medical implants. By providing a comprehensive system for wireless communication and data management, Ortho-tag supports medical device developers in advancing the capabilities of healthcare technology.
FemTherapeutics
Non Equity Assistance in 2024
FemTherapeutics is a Montreal-based medical device company dedicated to personalizing therapeutics in women’s health. It uses artificial intelligence and patient data to design customized gynecological prosthetics, initially focusing on improving the management of Pelvic Floor Disorders.
The Shape Sensing Company
Non Equity Assistance in 2024
The Shape Sensing Company specializes in advanced fiber optic 3D guidance technology that enables physicians to navigate medical devices within patient-specific anatomical models. Primarily focused on enhancing endovascular procedures, the company's innovative platform allows vascular surgeons and interventional radiologists to efficiently conduct approximately 2.8 million procedures annually in the United States, utilizing a proprietary 3D guidance workstation and guidewire. This technology not only aims to reduce procedure times and operational costs but also enhances patient outcomes by eliminating reliance on traditional X-ray imaging. Beyond its initial applications in medicine, The Shape Sensing Company is also poised to expand its impact across multiple industries, including aerospace, civil engineering, mining, and energy, through collaborations with various Original Equipment Manufacturer (OEM) partners developing 3D-guided devices.
CancerFree Biotech
Non Equity Assistance in 2024
CancerFree Biotech is a start-up focused on personalized cancer treatment through advanced technology. The company specializes in analyzing circulating tumor cells (CTCs) to create organoid systems, which assist healthcare professionals in developing tailored treatment strategies for patients at all stages of cancer. By utilizing its proprietary E.V.A. technology platform, CancerFree Biotech combines organoid culture systems with artificial intelligence for rapid expansion of CTCs into cancer-derived organoids (CDOs). This innovative approach supports various applications in cancer research, including cell therapy, cancer vaccines, and new drug development. The aim is to reduce ineffective drug use and alleviate the burden of frequent testing on patients during their treatment journey, ultimately enhancing the effectiveness of therapeutic interventions.
Dopl Technologies
Non Equity Assistance in 2024
Dopl Technologies, co-founded by an ex-Microsoft engineer and two Harvard-trained specialists, is dedicated to enhancing healthcare accessibility for underserved populations, particularly in rural areas. Recognizing the disparity in healthcare access, where specialists are predominantly located in urban centers, Dopl has developed a telerobotic ultrasound system. This innovative platform allows specialists to conduct diagnostic ultrasound procedures remotely, thus enabling patients in distant locations to receive timely and effective care. By leveraging this technology, Dopl aims to improve patient outcomes while also benefiting hospitals through increased revenue and reduced operational costs. The company’s mission focuses on ensuring that quality healthcare is available to all individuals, regardless of their geographical location.
DiaMonTech
Non Equity Assistance in 2024
Founded in 2015, DiaMonTech specializes in developing non-invasive medical diagnostic devices. Its proprietary photo-thermal detection technology enables accurate glucose level measurements without finger pricking or blood samples.
NIRAMAI Health Analytix
Non Equity Assistance in 2024
NIRAMAI Health Analytix Private Limited is a Bengaluru-based company that specializes in cancer screening through its innovative software, Thermalytix, which leverages machine intelligence to analyze thermography images. Founded in 2016, the company offers a range of hardware-software solutions tailored for various users, including a compact screening device for specialty hospitals, a handheld device for independent medical practitioners, and a portable solution designed for large-scale screenings. NIRAMAI's technology enables early detection of breast cancer, identifying tumors significantly smaller than those detectable by traditional methods. Their approach is non-contact, painless, and free of radiation, making it a low-cost and accessible option for women of all age groups to undergo frequent screenings without adverse effects. By facilitating early diagnosis, NIRAMAI aims to improve survival rates and enhance the quality of cancer care.
KA Imaging
Non Equity Assistance in 2024
KA Imaging Inc., founded in 2015 and based in Waterloo, Canada, specializes in designing and manufacturing advanced X-ray detectors for both medical and non-medical applications. The company's portfolio includes static X-ray detectors for identifying faults in pipes, dual-energy detectors for baggage screening at airports, dynamic detectors for inspecting engines with moving parts, and mammography detectors. Notably, KA Imaging has developed the world's first portable dual energy subtraction X-ray detector, which uses clinically proven technology to enhance sensitivity in detecting diseases such as pneumonia, nodules, fractures, and verifying catheter positions. This device, known as Reveal, has received FDA 510(k) clearance and is sold globally. The company employs a team of 20 full-time and 10 part-time/contract employees and holds 52 global patents and 17 issued US patents.
INOPASE
Non Equity Assistance in 2024
INOPASE is a medical device company focused on the development of wirelessly powered, closed-loop implantable neuromodulation technologies. The company is currently working on closed-loop sacral neuromodulation systems for the treatment of overactive bladder and closed-loop brain neuromodulation systems aimed at addressing epilepsy. INOPASE's platform utilizes advanced algorithms to enable personalized treatment plans, detecting symptoms and providing targeted stimulation therapy to patients with chronic neurological diseases.
AccurKardia
Non Equity Assistance in 2024
AccurKardia is an ECG-led diagnostics software company dedicated to enhancing the utility of ECG data as a diagnostic tool and biomarker to improve patient outcomes globally. The company specializes in cloud-based diagnostic solutions, including AccurECG™, an FDA-cleared software that provides fully automated, near real-time ECG interpretation. Additionally, AccurKardia developed AK+ Guard™, an AI-driven solution designed to detect hyperkalemia using Lead I ECG data, which aids patients with chronic kidney disease and end-stage renal disease in identifying dangerously high potassium levels at an earlier stage; this product has received FDA Breakthrough Device Designation. The company's aortic stenosis detection model, AK-AVS™, also received similar recognition. AccurKardia participated in the 2024 Cohort of MedTech Innovator and was selected for the inaugural American Heart Association's Heart and Brain Health Accelerator track, further emphasizing its commitment to advancing cardiac diagnostics and monitoring.
Cyted Health
Non Equity Assistance in 2024
Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.
Qritive
Non Equity Assistance in 2024
Qritive is a technology company that offers an artificial intelligence-powered diagnostic platform aimed at enhancing the accuracy and efficiency of cancer diagnoses. By utilizing advanced AI and natural language processing, Qritive's solution enables medical professionals to analyze microscopy images alongside patients' medical histories. This innovative approach allows hospitals to streamline their diagnostic processes, ultimately reducing costs and improving patient outcomes. With the rising incidence of cancer, Qritive addresses a critical need in the healthcare sector, equipping doctors with modern tools to aid in timely and precise cancer detection.
ACORAI
Non Equity Assistance in 2024
Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.
FibriCheck
Non Equity Assistance in 2024
FibriCheck is a medically certified application designed for the screening and monitoring of irregular heart rhythms, including atrial fibrillation. Functioning as a software-only solution, it allows users to measure their cardiac rhythm simply by placing a finger on their smartphone camera, making it accessible for use anytime and anywhere. The application automatically shares the collected data with medical professionals, facilitating quicker diagnoses and the development of appropriate treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, enabling it to leverage everyday smartphones and wearables. This innovative approach aims to enhance cardiovascular care by accurately detecting and tracking heart rhythm issues, while also helping individuals manage conditions such as high blood pressure and heart failure through user-friendly tools and customizable health plans.
iCE Neurosystems
Non Equity Assistance in 2024
iCE Neurosystems is a developer of an advanced neuromonitoring platform aimed at enhancing the diagnosis and treatment of brain injuries. The company combines innovative devices, cutting-edge software, and big-data analytics to deliver real-time insights into brain health. This integration enables healthcare professionals to receive early warnings and guide treatment for patients suffering from brain injuries, particularly in critical care settings. By providing revolutionary insights, iCE Neurosystems enhances the ability of doctors and nurses to diagnose and prevent brain injuries more effectively.
Ligence
Non Equity Assistance in 2024
Ligence is a Deep Tech startup based in Lithuania that combines medical expertise with artificial intelligence to automate echocardiography image analysis. The company develops tools for automatic recognition of heart image views, measurement, and report generation, accessible via a web-based platform and designed to integrate with hospital information systems. Its flagship solution, Ligence Heart, aims to reduce manual measurements by physicians and enhance consistency in heart ultrasound examinations through automated analysis. The offering targets clinicians and healthcare providers seeking to streamline cardiovascular imaging workflows.
Prevencio
Non Equity Assistance in 2024
Prevencio is a biotechnology company focused on developing innovative multi-proteomic biomarkers aimed at transforming blood tests for cardiovascular disease. Utilizing artificial intelligence, the company's biomarkers analyze established clinical data sets to create novel, multi-protein tests that are algorithmically scored. These tests enable clinicians to evaluate the effects of medications before and after administration, specifically concerning a composite risk of heart attack, stroke, and cardiac death. By leveraging advanced technology in biomarker development, Prevencio seeks to enhance the accuracy and effectiveness of cardiovascular diagnostics.
Swift Duct
Non Equity Assistance in 2024
Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.
Juniper Biomedical
Non Equity Assistance in 2024
Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at addressing pelvic health conditions. The company develops micro-implants that deliver targeted treatment by stimulating specific nerves, allowing for local modulation of innervation to muscles and organs. This innovative approach enables the provision of less invasive, safer, and more effective therapies for various conditions, including incontinence, sexual dysfunction, and chronic pain. By concentrating on precision treatment, Juniper Biomedical seeks to improve patient outcomes and enhance quality of life for individuals suffering from these health issues.
Neurovalens
Funding Round in 2024
Neurovalens is a UK-based company founded in 2013 that specializes in developing medical devices grounded in neuroscience, bioscience, and neurophysiology. The company's portfolio includes Stimu Slim and Modius, electronic headsets designed to address obesity through non-invasive neurostimulation. Neurovalens' technology focuses on transdermal activation of key brain regions to modulate autonomic function, circadian rhythms, and metabolic processes, offering healthcare providers drug-free treatment options for various health conditions. The company has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme to enhance its research and development activities.
DynaTechAnalytics
Pre Seed Round in 2024
Artificial intelligence driven software applications for digital health technologies. We train multimodal systems to be able to execute automated administration optimisation tasks as well as repetitive patient monitoring and classification solutions. We work closely with the NHS.
IFPx is a company focused on developing innovative monitoring technology for patients with chronic illnesses, beginning with heart failure. The company has created a patient monitoring device that directly analyzes fluid buildup, which is crucial for managing such conditions. By utilizing interstitial fluid pressure sensors, IFPx aims to enhance the monitoring capabilities available to healthcare professionals, thereby improving patient outcomes in heart failure management. The company's technology represents a significant advancement in the approach to chronic illness treatment, emphasizing the importance of real-time data in patient care.
Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.
StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.
Fingy3D is a company focused on making prosthetic devices accessible to all, specifically targeting the need for finger prosthetics. Utilizing an AI scanner, Fingy3D measures the dimensions of an individual's finger to create a custom-fit prosthetic. This innovative approach allows customers to receive 3D-printed prosthetic fingers conveniently at their doorsteps, enhancing the quality of life for those in need of such devices.
Neurava is a healthcare company focused on improving the lives of epilepsy patients through the development of non-invasive wearable diagnostic devices. These devices monitor critical biological signals associated with epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), offering a reliable solution for both patients and their caregivers. By providing accurate and timely alerts, especially during nighttime, Neurava's technology empowers caregivers to respond quickly and take preventive actions, thereby enhancing patient safety and peace of mind. The company's commitment to advancing medical device manufacturing and health diagnostics highlights its role in addressing the challenges faced by those with uncontrolled epilepsy.
Biotome
Non Equity Assistance in 2023
Biotome is a biotechnology research firm focused on developing advanced antibody diagnostic tests. The company specializes in identifying markers that indicate a high risk of stomach cancer, aiming to provide more precise and detailed disease information compared to current screening methods. By leveraging next-generation technology and precision immunology, Biotome's tests are designed to enhance the ability of medical professionals to treat patients effectively.
MicroTransponder
Non Equity Assistance in 2023
MicroTransponder is a medical device company that develops and commercializes implantable neurostimulation platforms aimed at treating neurological conditions. The company focuses on vagus nerve stimulation to promote neuroplasticity and functional recovery, with products including the Serenity System for tinnitus and Vivistim, an FDA-approved therapy for ischemic stroke survivors with moderate to severe upper-limb impairment more than six months post-stroke. Founded in 2007 and headquartered in Austin, Texas, MicroTransponder's technology combines paired vagus nerve stimulation with wireless delivery of targeted electrical impulses to enhance recovery after neurological injury and disease.
Proton Intelligence
Non Equity Assistance in 2023
Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases and enhance patient outcomes. The company focuses on continuous potassium monitoring, particularly for patients suffering from hyperkalemia associated with chronic kidney disease and other co-morbidities. Proton Intelligence's innovative platform provides accurate and real-time potassium measurements through interstitial fluid analysis, which correlates closely with blood levels. This capability is critical for enabling timely and informed decision-making regarding patient care, allowing clinicians and patients to effectively manage medications, dietary choices, and treatment options. By prioritizing precise monitoring, Proton Intelligence aims to significantly improve the health and lives of individuals affected by hyperkalemia.
Flow Neuroscience
Non Equity Assistance in 2023
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.
Xcision Medical Systems
Non Equity Assistance in 2023
Xcision Medical Systems, LLC is a medical technology company focused on developing innovative stereotactic radiotherapy solutions aimed at enhancing cancer treatment. The company specializes in manufacturing radiosurgery devices specifically designed for breast cancer treatment. Its technology utilizes stereotactic gamma irradiation, allowing for a complete course of radiation therapy to be delivered in a single, noninvasive session. This approach significantly reduces the duration of treatment compared to traditional methods, while minimizing radiation exposure to surrounding healthy tissues, including the lungs and heart. As a result, patients can resume their daily activities more quickly and with less discomfort, ultimately improving their quality of life. Additionally, Xcision's advancements enable healthcare professionals to enhance the overall quality of cancer care they provide.
PanTher Therapeutics
Non Equity Assistance in 2023
PanTher Therapeutics is a biotechnology company developing cancer drug-delivery technologies. Its core platform enables therapeutics to be delivered directly to the tumor site, reducing systemic toxicity and allowing higher drug concentrations at the target while enabling sustained treatment. This approach aims to improve therapeutic efficacy and outcomes for hard-to-treat cancers by maximizing drug exposure at the tumor while limiting exposure to healthy tissue. Headquartered in Cambridge, Massachusetts, PanTher Therapeutics is advancing investigational candidates, including a lead program in pancreatic cancer, to broaden the potential of precision delivery in oncology.
Neurava
Non Equity Assistance in 2023
Neurava is a healthcare company focused on improving the lives of epilepsy patients through the development of non-invasive wearable diagnostic devices. These devices monitor critical biological signals associated with epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), offering a reliable solution for both patients and their caregivers. By providing accurate and timely alerts, especially during nighttime, Neurava's technology empowers caregivers to respond quickly and take preventive actions, thereby enhancing patient safety and peace of mind. The company's commitment to advancing medical device manufacturing and health diagnostics highlights its role in addressing the challenges faced by those with uncontrolled epilepsy.
Perceptive Medical
Non Equity Assistance in 2023
Perceptive Medical is a developer of advanced medical devices aimed at enhancing blood pressure management in critical care settings, such as the intensive care unit (ICU) and operating room. The company's products are designed to integrate seamlessly into modern clinical workflows, providing healthcare providers with precise tools to address inefficiencies in patient care. By focusing on delivering measurable improvements in blood pressure therapy, Perceptive Medical plays a vital role in optimizing patient outcomes and supporting clinical professionals in their efforts to enhance overall care efficiency.
Xtremedy Medical
Non Equity Assistance in 2023
Xtremedy Medical, based at NUI Galway, specializes in manufacturing innovative surgical devices. These devices use electrical signals to treat bone and deep tissue infections, including diabetic foot ulcers. By targeting both surface and underlying infections, the company's technology helps doctors enhance treatment outcomes, reducing the risk of amputations and promoting faster patient recovery.
INBRAIN Neuroelectronics
Non Equity Assistance in 2023
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.
ImmersiveTouch
Non Equity Assistance in 2023
ImmersiveTouch Inc., established in Chicago, Illinois in 2005, specializes in developing, installing, and managing virtual reality simulators for medical training and patient engagement. The company's core offering is a high-fidelity immersive surgical simulator, housed within an 'immersive pod', which enables surgeons to interact with realistic 3D computer-generated anatomical models using haptic instrument replicas. This system provides lifelike visual, tactile, and audio sensations, facilitating skill development and pre-operative planning across various medical specialties such as core surgery skills, neurological surgery, spine, and ophthalmology. Additionally, ImmersiveTouch has expanded its offerings to include AI-driven digital surgery platforms, the Ikshana XR platform, which provides clinicians with data insights to enhance decision-making, improve patient outcomes, and optimize surgical resource allocation.
Covellus
Non Equity Assistance in 2023
Covellus is a medical device company focused on developing innovative platform technology for catheters used in minimally invasive surgeries. The company specializes in manufacturing vascular catheter devices and modular catheter systems, which allow physicians to customize existing devices to meet the specific needs of individual patients. By enhancing the versatility and adaptability of medical devices, Covellus aims to improve treatment outcomes in various medical procedures.
Endocision
Non Equity Assistance in 2023
Endocision is a medical device company focused on creating innovative minimally-invasive technologies for the diagnosis and treatment of lung diseases. The company specializes in robotic bronchoscopy technologies and a cryo-biopsy platform, which enhance the safety and effectiveness of procedures used by healthcare professionals. Endocision's solutions aim to facilitate the diagnosis and management of conditions such as interstitial lung disease and lung cancer, thereby improving patient outcomes through advanced medical interventions.
Universal Brain
Non Equity Assistance in 2023
Universal Brain is a company dedicated to advancing mental health treatment through innovative neurofeedback systems that leverage physiological data. It specializes in the research and development of advanced treatment algorithms powered by deep learning, which integrate magnetic resonance imaging and electroencephalogram data. Additionally, the company designs and manufactures portable electroencephalograph headsets that facilitate the application of its neurofeedback therapies. By providing health professionals with enhanced insights into brain data analysis, Universal Brain aims to improve psychiatric treatment outcomes and individualize mental health care.
Happitech
Non Equity Assistance in 2023
Happitech provides a CE-certified heart rate software development kit for Android and iOS that enables medical-grade vital signs monitoring via a smartphone camera using photoplethysmography. The SDK integrates into remote patient management applications to support continuous monitoring of heart rate, heart rate variability, and atrial fibrillation. Its on-device algorithms empower remote patient monitoring, telemedicine, and population health management, including cardiovascular screening, stroke prevention, and related health programs for patients, clinicians, and organizations worldwide.
Adcura
Non Equity Assistance in 2023
Adcura Inc., established in 2013, is a specialized medical device company dedicated to enhancing spine surgery outcomes through innovative, minimally invasive solutions. The company's portfolio comprises retractors, disposable accessories, and adjustable lumbar fusion devices, all designed to improve surgical efficiency and reduce post-operative complications for patients with spine-related issues. Adcura achieves this by focusing on precision technologies and advanced surgical techniques tailored to each patient's specific needs.
Sonavi Labs
Non Equity Assistance in 2023
Sonavi Labs, Inc. is a medical device and software company based in Baltimore, Maryland, founded in 2017. The company specializes in developing advanced technologies that analyze body sounds to aid in the diagnosis of respiratory diseases. By utilizing artificial intelligence, Sonavi Labs creates innovative products that enhance the capabilities of healthcare providers and improve patient experiences. Its devices are designed to detect and manage respiratory conditions by listening to bodily sounds and identifying abnormalities, thereby enabling healthcare professionals to monitor, diagnose, and potentially predict diseases effectively. Through its focus on modern medical solutions, Sonavi Labs aims to transform the landscape of respiratory health monitoring.
Hypervision Surgical
Non Equity Assistance in 2023
Hypervision Surgical develops an AI-powered hyperspectral imaging platform designed to enhance surgical precision, safety, and speed. The non-contact, non-invasive optical system splits light into multiple spectral bands to provide real-time, data-driven tissue characterization that can be visualized intraoperatively without contrast agents. This approach enables clinicians to assess tissue during procedures, potentially improving accuracy, reducing risk, and supporting decision-making throughout surgery.
Senseye
Non Equity Assistance in 2023
Senseye, Inc. is a Los Angeles-based company founded in 2015 that specializes in developing innovative smart contact lenses capable of non-invasively recording and analyzing information from users. These contact lenses are designed to infer human emotions, thoughts, and health states, thereby assisting in various applications such as market research, disease diagnosis, and early detection of medical conditions like strokes and heart attacks. By utilizing novel measurements of ocular physiology, Senseye aims to quantify cognitive abilities and psychological well-being, providing valuable insights into vital signs, attention, cognitive load, and fatigue. The company is committed to advancing technology that enhances emotional responses and mental health diagnostics, enabling clinicians to offer personalized care and effectively track patient outcomes over time.
Averto Medical
Non Equity Assistance in 2023
Averto Medical specializes in the manufacture of medical devices designed to improve outcomes for patients with gastrointestinal diseases. Their innovative solutions aim to facilitate minimally invasive colorectal tumor removal and other gastrointestinal surgeries, enabling healthcare professionals to provide optimal care.
Invenio Imaging
Non Equity Assistance in 2023
Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. It specializes in the development of advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and various materials. The company offers a multi-modal coherent Raman scattering microscope aimed at research and development as well as medical applications. Invenio Imaging's innovative platform technology is designed to facilitate intraoperative histology by providing high-resolution imaging that allows for the examination of specimens from multiple sites within a surgical cavity. The company was established based on research conducted by Professor Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.
Knowtex
Non Equity Assistance in 2023
Knowtex is a technology company that specializes in enhancing administrative efficiency within the healthcare sector. By leveraging artificial intelligence and voice technology, it captures and analyzes conversations between healthcare providers and patients to extract relevant medical information. This process allows Knowtex to generate detailed visit notes that include billing code suggestions and facilitate order entry. The platform aims to reduce the administrative burden on healthcare professionals, ensuring that visits are billed accurately and efficiently. Additionally, Knowtex fosters personable interactions with patients, contributing to improved overall care experiences. For further inquiries, the company provides an online inquiry form on its website.
Fingy3D
Non Equity Assistance in 2023
Fingy3D is a company focused on making prosthetic devices accessible to all, specifically targeting the need for finger prosthetics. Utilizing an AI scanner, Fingy3D measures the dimensions of an individual's finger to create a custom-fit prosthetic. This innovative approach allows customers to receive 3D-printed prosthetic fingers conveniently at their doorsteps, enhancing the quality of life for those in need of such devices.
NeuraStasis
Non Equity Assistance in 2023
NeuraStasis is focused on developing a non-invasive electrical neurostimulation method aimed at preventing strokes. The company's innovative device is designed to activate the body's natural oxygen-preserving and anti-inflammatory reflexes, which helps to protect brain tissue during critical moments. By preserving brain function, NeuraStasis enables patients to leave the hospital without disabilities, offering healthcare providers additional time to intervene effectively. This approach not only enhances patient outcomes but also represents a significant advancement in stroke treatment technology.
MACH32
Non Equity Assistance in 2023
MACH32 develops medical devices and drug-delivery solutions for pre-hospital and urgent-care trauma treatment. It designs safe, reliable tools that enable healthcare professionals to treat patients in the field while using protective equipment to reduce exposure to infectious aerosols, supporting rapid and safer intervention in emergency situations.
270Surgical
Non Equity Assistance in 2023
270Surgical Ltd. is a medical device company based in Netanya, Israel, founded in 2016. The company specializes in developing innovative surgical technologies, notably its flagship product, the SurroundScope System. This pioneering laparoscopic camera system features 270-degree wide field of view technology, which significantly enhances visualization during surgeries, thereby reducing the risk of 'off-screen' injuries and improving patient outcomes. The SurroundScope is designed to address common challenges faced in laparoscopic procedures, such as restricted visibility, lens fogging, and obstructions caused by surgical smoke. The system has received FDA clearance and is endorsed by prominent leaders in the field, establishing its credibility and effectiveness in enhancing surgical safety and efficiency.
Pumpinheart
Non Equity Assistance in 2023
Pumpinheart is a medical device company specializing in the development of an implantable left ventricular assist device (LVAD) for the treatment of heart failure with preserved ejection fraction (HFpEF). Their device, an electromedical pump, is designed to reduce left atrial pressure during diastole, improving heart function and potentially reducing hospitalizations. The pump is implanted in the left ventricle and operates in sync with the heart's natural rhythm, providing a minimally invasive treatment option for patients with HFpEF.
Purgo Scientific
Non Equity Assistance in 2023
Purgo Scientific is a medical device company focused on developing innovative solutions for targeted therapeutic drug delivery. The firm is working on a localized drug delivery device aimed at addressing the critical issue of biofilm infections in orthopedic surgery. This technology is designed to treat and prevent surgical site infections that can arise from the presence of indwelling orthopedic implants. By enabling precise medicine delivery, Purgo Scientific's device not only seeks to eradicate infections caused by biofilms but also has potential applications in managing pain and oncology-related health issues.
AMI
Non Equity Assistance in 2023
AMI Co., Ltd is a Japanese company based in Minamata-shi, established in 2015, that specializes in the manufacturing of medical equipment, primarily stethoscopes. In addition to producing medical devices, AMI is involved in healthcare consulting, offering services such as hospital management and clinical research. The company is also focused on developing telehealth solutions, including a telemedicine system that enhances remote medical consultations. Among its innovations is a video chat platform designed for remote auscultation, which allows for the separate transmission of heart sounds as both audible and visible data, thereby improving patient access to medical services through telemedicine initiatives.
Veinway
Non Equity Assistance in 2023
VeinWay is a medical device company focused on developing innovative solutions for the treatment of chronic venous occlusions caused by blockage or disease. The firm's primary offering is a specialized catheter designed to recanalize obstructed veins, providing physicians with a dedicated tool to navigate and clear complicated blockages. By facilitating the restoration of blood flow to the heart, VeinWay aims to transform the management of chronic venous disease and improve patient outcomes. The company's technology not only enables medical professionals to cross previously un-crossable obstructions but also aims to reduce the time required for such procedures.
Sparta Biomedical
Non Equity Assistance in 2023
Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.
JuneBrain
Non Equity Assistance in 2023
Founded in 2017, JuneBrain develops wearable, non-invasive imaging devices for multiple sclerosis (MS) patients to monitor their disease activity at home. This enables early detection of MS attacks and improves treatment efficacy monitoring.
Alyve Medical
Non Equity Assistance in 2023
Alyve Medical designs and manufactures medical devices that incorporate sensors for therapeutic and diagnostic use, focusing on musculoskeletal conditions. Its neuromuscular electrical stimulation (NMES) products stimulate neuroplasticity to enhance recovery, while its physical therapy and rehabilitation devices help patients regain and improve range of motion and function.
Nininger Medical
Non Equity Assistance in 2023
Nininger Medical is a medical technology company focused on developing innovative solutions for heart failure treatment. The company is currently working on a transcatheter tricuspid valve replacement device (TTVR) that utilizes proprietary 3D thin film technology. This advanced approach aims to provide effective heart valve therapies, helping to prevent structural heart failure in patients. Nininger Medical has gained recognition for its innovative efforts, recently receiving a Small Business Innovation Research grant from the National Science Foundation, which underscores its commitment to advancing healthcare solutions.
Opticyte
Non Equity Assistance in 2023
Opticyte, Inc. is a medical device company based in Seattle, Washington, specializing in the development of advanced algorithms and optical spectroscopy technology to monitor cellular oxygen levels. Founded in 2016 as a spinoff from the University of Washington, the company is focused on creating its first product, the Cell O2 Monitor, which aims to reduce the risk of organ failure. This innovative noninvasive oximeter measures oxygen levels within cells, enabling early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By providing clinicians with essential data, Opticyte's technology facilitates timely treatment decisions that can prevent multiple organ failure and improve patient outcomes. The company comprises teams with extensive experience in engineering, regulatory affairs, and communications, all dedicated to advancing medical device innovation.
Thermidas
Non Equity Assistance in 2023
Thermidas, a Finnish health technology company, specializes in developing and advancing infrared thermal imaging for diagnostic purposes. Its core product is thermal imaging software, designed to support screening, early diagnostics, and evaluation of treatment effectiveness. The technology enables swift and simple detection of asymmetric body temperature, which can indicate underlying health issues like inflammation, circulatory problems, and potential ulcers. This allows university hospitals and experienced clinicians to identify and diagnose conditions at earlier stages than traditional methods.
CerebraAI
Non Equity Assistance in 2023
CerebraAI is a digital diagnostic company focused on advancing stroke diagnosis through the application of artificial intelligence. Established in 2018, the company has developed its CEREBRA software, which utilizes deep learning algorithms to enhance the efficiency of CT machines. This technology enables the rapid detection of acute ischemic stroke within five minutes using non-contrast computed tomography. By providing community hospitals with tools for faster and more accurate diagnosis, CerebraAI aims to improve outcomes for neuroradiology and stroke patients during critical treatment windows.
CardieX
Non Equity Assistance in 2023
CardieX is a global health technology company focused on cardiovascular health management, including hypertension and vascular disorders. It designs, manufactures, and markets medical devices and digital health tools that measure cardiovascular risk, monitor arterial stiffness and central blood pressure, and support patient management across hospitals, clinics, research institutions, and pharmaceutical companies in the Americas, Europe, and the Asia-Pacific region. The company offers TeleHealth services with digital, e-commerce, and mobile tools enabling online connections with health coaches. Its products include devices based on patented arterial stiffness and central blood pressure technologies, and wearables with health analytics. CardieX collaborates with external partners to develop wearable sensors and hypertension programs. The company traces its origins to AtCor Medical and rebranded to CardieX in 2018. CardieX was founded in 1994 and is headquartered in Sydney, Australia.